[October 20, 2014] |
|
BBB Therapeutics Appoints Jan van Heek as Chairman of the Supervisory Board
LEIDEN, Netherlands --(Business Wire)--
BBB Therapeutics, a biopharmaceutical company pioneering treatments for
devastating brain diseases, today announced the appointment of Jan van
Heek as the Chairman of the Company's Supervisory Board effective
October 17, 2014. Mr. van Heek has been a non-executive Board Member
representing BBB Therapeutics' investor Antea Participaties since
January of 2014. He will assume the leadership of the Board from Patrick
Krol, Managing Partner at Aescap Venture, who has served as BBB
Therapeutics' Chairman since 2007. Mr. Krol will remain on the Board as
a non-executive Member.
"Jan's vast experience as a leading executive for one of the most
successful biopharmaceutical companies in the history of our industry
will be vital to BBB Therapeutics as the Company advances its clinical
candidates to treat key indications in neuro-oncology and
neuroinflammation," commented Dr. Anders Harfstrand, CEO. "We thank
Patrick for leading the Board for the past seven years and supporting
the Company through its dvelopment. We look forward to his continued
contributions."
Mr. van Heek brings over 25 years of executive experience in the biotech
industry to the Company. He is principal and partner of BioPoint Group,
where he advises biotechnology and other healthcare companies in
commercial strategy development, financing and business development
activities. From 1991 until 2009, Mr. van Heek held several executive
positions at Genzyme, including his tenure as Executive Vice President
of Genzyme Corporation, where he established Genzyme's European and
international offices and headed the global Therapeutics Group in the
US. Mr. van Heek has played a key role in building Genzyme's broad
portfolio of businesses and manufacturing structures worldwide. Prior to
Genzyme, he held various management positions at Baxter Healthcare
Corporation in Europe and in the US. Mr. van Heek has served as Chairman
of the Board of Biovex and as non-executive Member of the Boards of
PanGenetics, ViaCell and Zelos Therapeutics. He is currently a
non-executive Board Member and Chairman of the Audit Committee of Amarin
Corporation and has recently also joined the Board of Minerva
Neurosciences. Mr. van Heek holds an MBA from the University of
St.Gallen - School of Management, Economics, Law, Social Sciences and
International Affairs and an Executive degree from Stanford University
Graduate School of Business.
About BBB Therapeutics
BBB Therapeutics is pioneering innovative therapeutics to treat severe
brain disorders for which there are currently limited treatment options.
We are advancing a clinical pipeline of product candidates initially
focused on treating brain metastases and primary brain tumors as well as
indications in neuroinflammation. Our proprietary liposomal
G-Technology® facilitates entry of drugs into the brain while
simultaneously enabling sustained delivery of systemically administered
therapeutics.
[ Back To TMCnet.com's Homepage ]
|